CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Kyprolis for Multiple Myeloma (relapsed) – Details

Project Number PC0084-000
Brand Name Kyprolis
Generic Name Carfilzomib
Strength 60 mg per vial
Tumour Type Myeloma
Indication Multiple Myeloma (relapsed)
Funding Request In combination with dexamethasone alone in the treatment of patients with relapsed multiple myeloma who have received 1 to 3 prior lines of therapy
Review Status Complete
Pre Noc Submission Yes
NOC Date November 22, 2016
Manufacturer Amgen Canada Inc.
Sponsor Amgen Canada Inc.
Submission Date September 9, 2016
Submission Deemed Complete September 16, 2016
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ September 23, 2016
Check-point meeting November 1, 2016
pERC Meeting January 19, 2017
Initial Recommendation Issued February 2, 2017
Feedback Deadline ‡ February 16, 2017
pERC Reconsideration Meeting March 16, 2017
Final Recommendation Issued March 30, 2017
Notification to Implement Issued April 17, 2017
Therapeutic Area Multiple Myeloma (relapsed)
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.